N References

The Parkinson's-Reversing Breakthrough

Parkinson Disease eBook

Get Instant Access

1. Cajal SR, May RT. Degeneration and Regeneration of the Nervous System. New York: Hafner, 1959.

2. Filogamo G, Vernadakis A, Gremo F, Privat AM, Timiras PS, eds. Brain plasticity: Development and Aging, Advances in Experimental Medicine and Biology. Vol. 429. New York: Plenum Press, 1997.

3. Freund H, Sabel BA, Witte OW, eds. Brain plasticity, in Advances in Neurology. Vol. 73. Philadelphia: Lippincott-Raven, 1997.

4. Eriksson PS, Perfilieva E, Bjork-Eriksoon T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998; 4(11):1313-1317.

5. Fuchs E, Gould E. In vivo neurogenesis in the adult brain: regulation and functional implications. Eur J Neurosci 2000; 12(7): 2211-2214.

6. Lowenstein DH, Parent JM. Brain, heal thyself. Science 1999; 283 (5405):1126-1127.

7. Berchtold NC, Chinn G, Chou M, et al. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 2005; 133(3): 853-861.

8. Cotman CW. Axon sprouting and regeneration.In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds. Basic Neurochemistry. Philadelphia:Lippincott-Raven, 1999.

9. Helmuth L. Glia tell neurons to build synapses. Science 2001; 291 (5504):569-570.

10. Ullian EM, Chistopherson KS, Barres BA. Role for glia in synaptogenesis. Glia 2004; 47(3):209-216.

11. Christopherson KS, Ullian EM, Stokes CC, et al. Thrombospodins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 2005; 120(3):421-433.

12. Pascual O, Casper KB, Kubera C, et al. Astrocytic purinergic signaling. Sciene 2005; 310(5745):113-116.

13. Shaham S. Glia-neuron interactions in nervous system function and development. Curr Top Dev Biol 2005; 69:39-66.

14. Higashigawa K, Seo A, Sheth N, et al. Effects of estrogens and thyroid hormone on development and aging of astrocytes and oligodendrocytes. In: DeVellis J, ed. Neuroglia in the Aging Brain. Totowa:Humana Press, 2001:245-256.

15. Goya L, Feng PT, Aliabadi S, et al. Effect of growth factors on the in vitro growth and differentiation of early and late passage C6 glioma cells. Int J Dev Neurosci 1996; 14(4):409-417.

16. Isaeff M, Goya L, Timiras PS. Alterations in the growth and protein content of human neuroblastoma cells in vitro induced by thyroid hormones, stress and ageing. J Reprod Fertil Suppl 1993; 46:21-33.

17. Timiras PS. Thyroid hormones and the developing brain. In: Meisami E, Timiras PS, eds. Handbook of Human Growth and Developmental Biology.Vol. I: Part C. New York: CRC Press, 1988: 59-82.

18. Timiras PS, Yaghmaie F, Saeed O, et al. The ageing phenome: caloric restriction and hormones promote neural cell survival, growth, and de-differentiation. Mech Ageing Dev 2005; 126:3-9.

19. Bjorklund A, Lindvall O. Cell replacement therapies for c ntral nervous system disorders. Nat Neurosci 2000; 3(6):537-544.

20. Gage FH. Brain, repair yourself. Sci Am 2003; 289(3):46-53.

21. Vogel G. Cell biology. Stem cells: new excitement, persistent questions. Science 2000; 290(5497):1672-1674.

22. Freed CR, Leehey MA, Zawada M, et al. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol 2003; 250(suppl 3):44-46.

23. Weber W, Butcher J. Doubts over cell therapy for Parkinson's disease. Lancet 2001; 357(9259):859.

24. Vogel G. Parkinson's research: fetal cell transplant trial draws fire. Science 2001; 291(5511):2060-2061.

25. Brundin P, Karlsson J, Emgard M, et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 2000; 9(2):179-195.

26. Waldemar G, Hogh P, Paulson OB. Functional brain imaging with single-photon emission computed tomography in the diagnosis of Alzheimer's disease. Int Psychogeriatr 1997; 9 (suppl 1): 223-227.

27. Loessner A, Alavi A, Lewandrowski KU, et al. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995; 36(7):1141-1149.

28. Budinger TF. Brain imaging in normal aging and in Alzheimer's disease. In:Sternberg H, Timiras PS, eds. Studies of Aging. New York: Springer, 1999:182-206.

29. Newberg AB, Alavi A, Payer F. Single photon emission computed tomography in Alzheimer's disease and related disorders. Neuroimaging Clin N Am 1995; 5(1):103-123.

30. De Leon MJ, Convit A, DeSanti S, et al. The hippocampus in aging and Alzheimer's disease. Neuroimaging Clin N Am 1995; 5(1): 1-17.

31. Sacher GA. Maturation and longevity in relation to cranial capacity in hominid evolution. In: Tuttle RH, ed. Primate Functional Morphology and Evolution. Mouton: The Hague, 1975:417-442.

32. Brazier MAB. The Historical Development of Neurophysiology. Washington, DC: American Physiological Society, 1959.

33. Brizzee KR, Sherwood N, Timiras PS. A comparison of cell populations at various depth levels in cerebral cortex of young adult and aged Long-Evans rats. J Gerontol 1968; 23(3): 289-297.

34. Brizzee KR. Neuron aging and neuron pathology. In: Johnson HA, ed. Relations Between Normal Aging and Disease. Vol. 28. New York: Raven Press, 1985:191-224.

35. Long JM, Mouton PR, Jucker M, et al. What counts in brain aging? Design-based stereological analysis of cell number. J Gerontol A Biol Sci Med Sci 1999; 54(10):B407-B417.

36. Sjobeck M, Dahlen S, Englund E. Neuronal loss in the brainstem and cerebellum—part of the normal aging process? A morpho-metric study of the vermis cerebelli and inferior olivary nucleus. J Gerontol 1999; 54(9):B363-B368.

37. Gould E, Reeves AJ, Graziano MS, et al. Neurogenesis in the neocortex of adult primates. Science 1999; 86(5439):548-552.

38. Muir JL. Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav 1997; 56(4):687-696.

39. Sian J, Gerlach M, Youdim MB, et al. Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm 1999; 106(5-6): 443-476.

40. Scheibel ME, Lindsay RD, Tomiyasu U, et al. Progressive dendritic changes in aging human cortex. Exp Neurol 1975; 47 (3):392-403.

41. Flood DG, Buell SJ, Defiore CH, et al. Age-related dendritic growth in dentate gyrus of human brain is followed by regression in the "oldest old". "Brain Res 1985; 345(2):366-368.

42. Flood DG, Coleman PD. Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease. Prog Brain Res 1990; 83:435-443.

43. Cho HS, Kim SS, Choi W, et al. Age-related changes of mRNA expression of amyloid precursor protein in the brain of senescence-accelerated mouse. Comp Biochem Physiol B Biochem Mol Biol 1995; 112(2):399-404.

44. Neill D. Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neurodegeneration 1995; 4(2):217-232.

45. Goldberger AL. Is the normal heartbeat chaotic or homeostatic? News Physiol Sci 1991; 6:87-91.

46. Lipsitz LA, Goldberger AL. Loss of "complexity" and aging. Potential applications of fractals and chaos theory to senescence. J Am Med Assoc 1992; 267(13):1806-1809.

47. Freeman WJ. Societies of Brains. A Study in the Neuroscience of Love and Hate. Hillsdale: Lawrence Erlbaum Associates, 1995.

48. Fries P, Reynolds JH, Rorie AE, et al. Modulation of oscillatory neuronal synchronization by selective visual attention. Science 2001; 291(5508):1560-1563.

49. Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry 1994; 57(2): 129-133.

50. Brizzee KR, Cancilla PA, Sherwood N, et al. The amount and distribution of pigments in neurons and glia of the cerebral cortex. Autofluorescence and ultrastructural studies. J Gerontol 1969; 24 (2):127-135.

51. Morrison BM, Hof PR, Morrison JH. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann Neurol 1998; 44 (3 suppl 1):S32-S44.

52. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55(3):259-272.

53. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 1998; 8 (2):299-324.

54. Graves AB, Bowen JD, Rajaram L, et al. Impaired olfaction as a marker for cognitive decline. Interaction with apolipoprotein E4 status. Neurology 1999; 53(7):1480-1487.

55. Burns A. Might olfactory dysfunction be a marker of early Alzheimer's disease? Lancet 2000; 355(9198):84-85.

56. Lee VM. Disruption of the cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol 1995; 5(5):663-668.

57. Finch CE, Cohen D. Aging, metabolism, and Alzheimer's disease: review and hypotheses. Exp Neurol 1997; 143(1):82-102.

58. Schoenfeld TA, Obar RA. Diverse distribution and function of fibrous microtubule-associated proteins in the nervous system. Int Rev Cytol 1994; 151:67-137.

59. Brady ST. Motor neurons and neurofilaments in sickness and in health. Cell 1993; 73(1):1-3.

60. Mandelkow EM, Schweers O, Drewes G, et al. Structure, micro-tubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 1996; 777:96-106.

61. Spillantini M, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998; 21(10):428-433.

62. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293(5534):1487-1491.

63. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apoprotein E4 genotype. Exp Neurol 1994; 125(2):163-171.

64. Nothias F, Boyne L, Murray M, et al. The expression and distribution of tau proteins and messenger RNA in rat dorsal root ganglion neurons during development and regeneration. Neuroscience 1995; 66(3):707-719.

65. Kosik KS, Shimura H. Phosphorylated tau and the neuro-degenerative foldopathies. Biochim Biophys Acta 2005; 1739 (2-3):298-310.

66. Cole GM, Timiras PS. Ubiquitin-protein conjugates in Alzheimer's lesions. Neurosci Lett 1987; 79(1-2):207-212.

67. Andersen JK. What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease? Mech Ageing Dev 2000; 118 (1-2):15-22.

68. Thomas RJ. Excitatory amino acids in health and disease. J Am Geriatr Soc 1995; 43(11):1279-1289.

69. Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 1994; 63:175-195.

70. Haley JE. Gases as neurotransmitters. Essays Biochem 1998; 33: 79-81.

71. Ebadi M, Murrin LC, Pfeiffer RF. Hippocampal zinc thionein and pyridoxal phosphate modulate synaptic functions. Ann N Y Acad Sci 1990; 585:189-201.

72. Golub MS, Keen CL, Gershwin ME, et al. Developmental zinc deficiency and behavior. J Nutr 1995; 125(suppl 8): 2263S-2271S.

73. Rosahl TW, Spillane D, Missler M, et al. Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 1995; 375 (6531):488-493.

74. Timiras PS, Hudson DB, Segall PE. Lifetime brain serotonin: regional effects of age and precursor availability. Neurobiol Aging 1984; 5(3):235-242.

75. Andersen JK. Does neuronal loss in Parkinson's disease involve programmed cell death? Bioessays 2001; 23(7):640-646.

76. McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology 1993; 111(4): 391-401.

77. Garcia-Ladona FJ, Palacios JM, Probst A, et al. Excitatory amino acid AMPA receptor mRNA localization in several regions of normal and neurological disease affected human brain. An in situ hybridization histochemistry study. Brain Res Mol Brain Res 1994; 21(1-2):75-84.

78. Gerlach M, Riederer P, Youdim MB. Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and excitotoxic amino acids. Adv Neurol 1996; 69: 177-194.

79. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340(25):1970-1980.

80. Nadeau SE. Clinical decisions: Parkinson's disease. J Am Geriatr Soc 1997; 45(2):233-240.

81. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996; 103(8-9):987-1041.

82. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998; 43(5):551-554.

83. Fox SH, Brotchie JM. New treatments for movement disorders? Trends Pharmacol Sci 1996; 17(10):339-342.

84. Gerlach M, Reichmann H, Riederer P. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2005; 20 (5):643-644.

85. Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology 1996; 47(6 suppl 3):S137-S145.

86. Waters C. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. J Am Geriatr Soc 2000; 48(6):692-698.

87. Andersen JK. Use of genetically engineered mice as models for exploring the role of oxidative stress in neurodegenerative diseases. Front Biosci 1998; 3:c8-c16.

88. Jha N, Andersen JK. Loss of glutathione (GSH) in Parkinson's Disease: how does GSH act to protect dopaminergic neurons of the substantia nigra? In:Pandalai SG, ed. Recent Research Developments in Neurochemistry. Vol. 2. Kerala: Research Signpost, 1999:99-108.

89. Yanteri F, Andersen JK. The role of iron in Parkinson's disease and MPTP toxicity. IUBMB Life 1999; 48(2):139-141.

90. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275(5301):838-841.

91. Kordower JH, Emborg ME, Bloch J, et al. Neurodegenera -tion prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290(5492): 767-773.

92. Zetterstrom RH, Solomin L, Jansson L, et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997; 276(5310): 248-250.

93. Lang AE, Lozano A, Montgomery EB, et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. Adv Neurol 1999; 80:575-583.

94. Dostrovsky JO, Davis KD, Lee L, et al. Electrical stimulation-induced effects in the human thalamus. Adv Neurol 1993; 63: 219-229.

95. Yudofsky SC. Parkinson's disease, depression, and electrical stimulation of the brain. N Engl J Med 1999; 340(19):1500-1502.

96. Berardelli A, Rona S, Inghilleri M, et al. Cortical inhibition in Parkinson's disease: a study with paired magnetic stimulation. Brain 1996; 119(Pt 1):71-77.

97. Bejjani BP, Damier P, Amulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340(19):1476-1480.

98. Fischbach GD, McKhann GM. Cell therapy for Parkinson's disease. N Engl J Med 2001; 344(10):763-765.

99. Olson L. Biomedicine. Combating Parkinson's disease—step three. Science 2000; 290(5492):721-724.

100. McKay R. Stem cells in the central nervous system. Science 1997; 276(5309):66-71.

101. Brustle O, Jones KN, Learish RD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 1999; 285(5428):754-756.

102. Wakayama T, Tabar V, Rodriguez I, et al. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science 2001; 292(5517):740-743.

103. Luquin MR, Montoro RJ, Guillen J, et al. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999; 22(4):743-750.

104. Colman DR. Neurites, synapses and cadherins reconciled. Mol Cell Neurosci 1997; 10(1-2):1-6.

105. Serafini T. An old friend in a new home: cadherins at the synapse. Trends Neurosci 1997; 20(8):322-323.

106. Walsh FS, Doherty P. Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 1997; 13:425-456.

107. Colman DR, Filbin MT. Cell Adhesion Molecules. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven, 1999:139-154.

108. Yew DT, Wong HW, Li WP, et al. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp Gerontol 1999; 34(1):117-133.

109. Ronn LC, Berezin Y, Bock E. The neural cell adhesion molecule in synaptic plasticity and ageing. Int J Dev Neurosci 2000; 18(2-3): 1993-1999.

110. Thoenen H. Neurotrophins and activity-dependent plasticity. Brain Res 2000; 128:183-191.

111. Mufson EJ, Kroin JS, Sendera TJ, et al. Distribution and retrograde transport of trophic factors in the central nervous system:

functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57(4):451-484.

112. Hadjiconstantinou M, Neff NH. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J Neurochem 1998; 70(4):1335-1345.

113. Dreyfus H, Sabel J, Heidinger Y, et al. Gangliosides and neurotrophic growth factors in the retina. Molecular interactions and applications as neuroprotective agents. Ann N Y Acad Sci 1998; 845:240-252.

114. Timiras PS, Hudson DB, Oklund S. Changes in central nervous system free amino acids with development and aging. Prog Brain Res 1973; 40(0):267-275.

115. Clarke DD, Sokoloff L. Circulation and energy metabolism of the brain. In:Siegel G, Agranoff BW, Albers RW, Fisher SK, Uhler / surname> MD, eds. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven, 1999:637-670.

116. Hoyer S. Oxidative energy metabolism in Alzheimer's brain. Studies in early-onset and late-onset cases. Mol Chem Neuropathol 1992; 16(3):207-224.

117. Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 2000; 11:213-328.

118. Gafni A. Structural modifications of proteins during aging. J Am Geriatr Soc 1997; 45(7):871-880.

119. Hardy J, Gwinn-Hardy K. Neurodegenerative disease: a different view of diagnosis. Mol Med Today 1999; 5(12):514-517.

120. de Boer AG, Gaillard PJ. Blood-brain barrier and recovery. J Neural Transm 2006; 113(4):455-462.

121. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999; 22:11-28.

Was this article helpful?

0 0
Your Metabolism - What You Need To Know

Your Metabolism - What You Need To Know

If you have heard about metabolism, chances are it is in relation to weight loss. Metabolism is bigger than weight loss, though, as you will learn later on. It is about a healthier, better you. If you want to fire up your metabolism and do not have any idea how to do it, you have come to the right place. If you have tried to speed up your metabolism before but do not see visible results, you have also come to the right place.

Get My Free Ebook


Post a comment